NEW YORK, Feb. 9 (GenomeWeb News) - Transgenomic and NorDiag announced today that they have signed an exclusive license and supply agreement to collaborate in colorectal and pancreatic cancer diagnostics.
Terms of the deal call for Transgenomic to give NorDiag exclusive European commercial rights to use its Wave system in exchange for an undisclosed licensing fee and commitment to annual purchases by NorDiag.
NorDiag uses the Wave system in its Genefec test. The platform is "integral to the automation of the Genefec test," said the companies in a statement.
NorDiag has offices in London and Bergen, Norway. The Genefec test is available as a clinical diagnostic in Norway and Sweden.